company background image
NNOX

Nano-X Imaging NasdaqGM:NNOX Stock Report

Last Price

US$10.38

Market Cap

US$540.6m

7D

1.6%

1Y

-58.5%

Updated

27 May, 2022

Data

Company Financials +
NNOX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

NNOX Stock Overview

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source.

Nano-X Imaging Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Nano-X Imaging
Historical stock prices
Current Share PriceUS$10.38
52 Week HighUS$34.50
52 Week LowUS$8.23
Beta0
1 Month Change7.01%
3 Month Change4.32%
1 Year Change-58.48%
3 Year Changen/a
5 Year Changen/a
Change since IPO-52.17%

Recent News & Updates

Shareholder Returns

NNOXUS Medical EquipmentUS Market
7D1.6%2.9%5.9%
1Y-58.5%-14.9%-10.2%

Return vs Industry: NNOX underperformed the US Medical Equipment industry which returned -15.8% over the past year.

Return vs Market: NNOX underperformed the US Market which returned -15.1% over the past year.

Price Volatility

Is NNOX's price volatile compared to industry and market?
NNOX volatility
NNOX Average Weekly Movement13.2%
Medical Equipment Industry Average Movement10.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: NNOX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: NNOX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011186Erez Meltzerhttps://www.nanox.vision

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode.

Nano-X Imaging Fundamentals Summary

How do Nano-X Imaging's earnings and revenue compare to its market cap?
NNOX fundamental statistics
Market CapUS$540.59m
Earnings (TTM)-US$70.75m
Revenue (TTM)US$3.11m

173.7x

P/S Ratio

-7.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NNOX income statement (TTM)
RevenueUS$3.11m
Cost of RevenueUS$6.54m
Gross Profit-US$3.43m
Other ExpensesUS$67.32m
Earnings-US$70.75m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.36
Gross Margin-110.25%
Net Profit Margin-2,273.36%
Debt/Equity Ratio1.4%

How did NNOX perform over the long term?

See historical performance and comparison

Valuation

Is Nano-X Imaging undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.95x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NNOX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NNOX's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: NNOX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Medical Equipment industry average.

PE vs Market: NNOX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NNOX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NNOX is good value based on its Price-To-Book Ratio (2x) compared to the US Medical Equipment industry average (2.5x).


Future Growth

How is Nano-X Imaging forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


68.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NNOX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: NNOX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NNOX's is expected to become profitable in the next 3 years.

Revenue vs Market: NNOX's revenue (95.1% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: NNOX's revenue (95.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NNOX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Nano-X Imaging performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-47.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NNOX is currently unprofitable.

Growing Profit Margin: NNOX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NNOX is unprofitable, and losses have increased over the past 5 years at a rate of 47.9% per year.

Accelerating Growth: Unable to compare NNOX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NNOX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.1%).


Return on Equity

High ROE: NNOX has a negative Return on Equity (-25.54%), as it is currently unprofitable.


Financial Health

How is Nano-X Imaging's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NNOX's short term assets ($78.1M) exceed its short term liabilities ($51.0M).

Long Term Liabilities: NNOX's short term assets ($78.1M) exceed its long term liabilities ($19.2M).


Debt to Equity History and Analysis

Debt Level: NNOX has more cash than its total debt.

Reducing Debt: Insufficient data to determine if NNOX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NNOX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NNOX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 78.3% each year.


Dividend

What is Nano-X Imaging current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NNOX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NNOX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NNOX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NNOX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NNOX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Erez Meltzer (64 yo)

0.33

Tenure

Mr. Erez I. Meltzer is a Director at Turpaz Industries Ltd since May 18, 2021. He served as Chief Executive Officer at Nano-X Imaging Ltd. since January 2022 and also serves as its Director since December...


Leadership Team

Experienced Management: NNOX's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: NNOX's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.


Top Shareholders

Company Information

Nano-X Imaging Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Nano-X Imaging Ltd.
  • Ticker: NNOX
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$540.595m
  • Shares outstanding: 52.08m
  • Website: https://www.nanox.vision

Number of Employees


Location

  • Nano-X Imaging Ltd.
  • Communications Center
  • Neve Ilan
  • 9085000
  • Israel

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/27 00:00
End of Day Share Price2022/05/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.